3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow CD20 Positive: new trials by email Literature Review of CD20 Positive trials Research Report on CD20 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Carboplatin, Etoposide, Ibrutinib - CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2014-09-12 | 2018-01-26 |
| Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma Ipilimumab, Laboratory Biomarker Analysis, Rituximab - CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 32 | 2012-11-19 | 2018-04-11 |
| Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bendamustine - CD20 Positive, Chronic Lymphocytic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 60 | 2009-02-17 | 2019-06-03 |
Lymphoma, Large B-Cell, Diffuse (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Lymphoma, B-Cell (2) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, B-Cell (1)
CT-P10 (3) · Rituximab (3) · Antilymphocyte Serum (1) · Bendamustine Hydrochloride (1) · CTLA-4 Antigen (1) · Carboplatin (1) · Etoposide (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Ifosfamide (1) · Ipilimumab (1) · Methotrexate (1) · Tacrolimus (1) · fludarabine (1) · ibrutinib (1)
National Cancer Institute (NCI) (2) · M.D. Anderson Cancer Center (1)
United States (3)
Craig Sauter (1) · Issa Khouri, MD (1) · Joseph Tuscano (1)
P30CA008748 (1), P30CA016672 (1), P30CA033572 (1), U01CA062505 (1), UM1CA186704 (1), UM1CA186717 (1)